Evidence map›Paper›PMID 36194021›Full record

ArticleJournal of virology2022

Rift Valley Fever Virus Infects the Posterior Segment of the Eye and Induces Inflammation in a Rat Model of Ocular Disease.

Madeline M Schwarz, Kaleigh A Connors, Katherine A Davoli, Cynthia M McMillen, Joseph R Albe, Ryan M Hoehl, Matthew J Demers, Safder S Ganaie, David A Price, Daisy W Leung and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Laboratory Animal Models for Rift Valley Fever Virus Disease.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Madeline M SchwarzCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.
Kaleigh A ConnorsCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.
Katherine A DavoliOphthalmic and Visual Sciences Research Center, Department of Ophthalmology, University of Pittsburghgrid.21925.3d School of Medicine, Pittsburgh, Pennsylvania, USA.
Cynthia M McMillenCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9211-7908
Joseph R AlbeCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.
Ryan M HoehlCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.
Matthew J DemersCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.
Safder S GanaieDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
David A PriceDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Daisy W LeungDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.ORCID 0000-0002-0418-9707
Anita K McElroyCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6764-7536
Douglas S ReedCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-0076-9023
Amy L HartmanCenter for Vaccine Research, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-0857-2973
University of Pittsburgh · USWashington University in St. Louis · US

Funding

Virus Production and Manipulation of Protein/Gene Expression ModuleP30EY008098 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ethan A Rossi · 1989 to 2026
$17.8M
Immunology of Infectious DiseaseT32AI060525 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JoAnne L. Flynn · 2005 to 2026
$5.3M
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and PathogenesisR01AI161765 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K., HARTMAN, AMY L · 2021 to 2025
$3.7M
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetusesR01AI150792 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARTMAN, AMY L · 2020 to 2025
$3.7M
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley FeverR01NS101100 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARTMAN, AMY L · 2017 to 2021
$1.7M
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virusR21AI163603 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARTMAN, AMY L · 2021 to 2022
$442k
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat ModelR21NS088326 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARTMAN, AMY L · 2015 to 2016
$419k
NEI NIH HHS P30 EY008098NIAID NIH HHS R01 AI150792NIAID NIH HHS R01 AI161765NIAID NIH HHS R21 AI163603NIAID NIH HHS T32 AI060525NINDS NIH HHS R01 NS101100Wellcome Trust
6 · The paper itself

Abstract

People infected with the mosquito-borne Rift Valley fever virus (RVFV) can suffer from eye-related problems resulting in ongoing vision issues or even permanent blindness. Despite ocular disease being the most frequently reported severe outcome, it is vastly understudied compared to other disease outcomes caused by RVFV. Ocular manifestations of RVFV include blurred vision, uveitis, and retinitis. When an infected individual develops macular or paramacular lesions, there is a 50% chance of permanent vision loss in one or both eyes. The cause of blinding ocular pathology remains unknown in part due to the lack of a tractable animal model. Using 3 relevant exposure routes, both subcutaneous (SC) and aerosol inoculation of Sprague Dawley rats led to RVFV infection of the eye. Surprisingly, direct inoculation of the conjunctiva did not result in successful ocular infection. The posterior segment of the eye, including the optic nerve, choroid, ciliary body, and retina, were all positive for RVFV antigen in SC-infected rats, and live virus was isolated from the eyes. Proinflammatory cytokines and increased leukocyte counts were also found in the eyes of infected rats. Additionally, human ocular cell lines were permissive for Lrp1-dependent RVFV infection. This study experimentally defines viral tropism of RVFV in the posterior segment of the rat eye and characterizes virally-mediated ocular inflammation, providing a foundation for evaluation of vaccines and therapeutics to protect against adverse ocular outcomes.

Indexed as

Eye DiseasesRift Valley FeverRift Valley fever virusAerosolsAnimalsBlindnessCytokinesHumansInflammationRatsRats, Sprague-DawleyAerosolsCytokinesaerosolbunyaviruseye diseaseocular diseaseretinitisRift Valley feveruveitis

Identifiers

PMID36194021
PMCPMC9599513
OpenAlexW4301391300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.